<DOC>
	<DOCNO>NCT00579150</DOCNO>
	<brief_summary>This observational , prospective cohort study describe pregnancy outcome woman pre-existing ( prior pregnancy ) type 2 diabetes expose formulation exenatide pregnancy . The pregnancy registry compare occurrence pregnancy outcomes interest collect prospective group woman pre-existing type 2 diabetes expose one antidiabetic medication exenatide pregnancy . Insulin exposures acceptable group must addition one antidiabetic medication non-exenatide group . The primary study objective evaluate percentage major birth defect ( i.e. , cause significant functional cosmetic impairment , require surgery , life-limiting ) follow use exenatide pregnancy treatment type 2 diabetes compare percentage major birth defect follow use one antidiabetic medication exenatide pregnancy treatment type 2 diabetes . The secondary objective Exenatide Pregnancy Registry evaluate percentage adverse pregnancy outcome ( e.g. , spontaneous abortion , stillbirth , preterm birth ) potential impact exenatide use breastfeed among pregnancy birth woman use exenatide pre-existing type 2 diabetes : This study conduct United States ( US ) . Enrollment Registry voluntary . The Exenatide Pregnancy Registry sponsor AstraZeneca manage INC Research , LLC . The scientific conduct analysis Registry overseen Registry Review Committee ( RRC ) consist expert maternal fetal medicine , teratology/genetics , epidemiology , type 2 diabetes pregnancy and/or pediatrics .</brief_summary>
	<brief_title>Exenatide Pregnancy Registry - Type 2 Diabetes Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Pregnancy Diabetics</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>The subject must meet following eligibility criterion participation registry : Is pregnant least 18 year age time enrollment Had diagnosis type 2 diabetes prior pregnancy Does know pregnancy outcome time enrollment Has knowledge exist structural chromosomal defect detect prenatal test prior enrollment Had expose immediate release formulation exenatide ( e.g . BYETTA® ) noninsulin antidiabetic medication exenatide first day last menstrual period ( insulin use allow group ) . OR participant expose extended release formulation exenatide ( e.g . BYDUREON® ) within 8 week first day last menstrual period Is willing able provide inform consent authorization pregnancy registry contact obstetric HCP , diabetes HCP , infant 's pediatric HCP ( complete contact information practitioner , different , available ) Is able understand spoken English Spanish</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Birth Defects</keyword>
	<keyword>High Risk Pregnancy</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>